Tags : Highlights

Roche Highlights its Response to COVID-19 Pandemic

Shots: On Mar 19, 2020, the company initiates the global P-III study in collaboration with BARDA to assess the efficacy of Actemra/RoActemra (tocilizumab, IV) + SOC vs PBO + SOC in hospitalized patients with severe COVID-19 pneumonia Roche facilitates the delivery and production of Actemra and is working continuously to increase the availability of COVID […]Read More

PharmaShots’ Key Highlights of Fourth Quarter 2019

1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date – Oct 01, 2019 Product – Zirabev (biosimilar, bevacizumab) The biosimilar was launched in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept […]Read More

Sangamo Highlights its Genomic Medicine Pipeline at R&D Day 2019

Shots: Sangamo provides an update on its pre/ clinical pipeline and emphasizes on its global capabilities across clinical science, operations, product development and manufacturing at its R&D day The company highlights the completion of IND transfer to Pfizer for its gene therapy candidate, SB-525 with the expected onset of its P-III study in 2020 by […]Read More

Novartis Highlights its Blockbuster Portfolio at R&D Day 2019

Shots: Novartis reports that it has 60 projects in P-II with expected 10+ products to enter in P-III study in 2020 & 2021 while 90% of them are first-in-class or first-in-indication therapies. Novartis emphasizes its focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms Novartis presents its emerging assets including Iscalimab […]Read More

PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired […]Read More

PharmaShots’ Key Highlights of Second Quarter 2019

The second quarter of 2019 has ended with major acquisitions in pharma and biotech industry. Moving with the latest acquisition of Allergan for $63B by AbbVie focusing on to generate revenue with addition of Allergan’s medical aesthetics and ophthalmology portfolio. Prior to that, Pfizer acquired Array Biopharma for $11.4B to expand its oncology portfolio. Some […]Read More